IMM vs. ETX, TRX, SBTX, COS, C4XD, DDDD, OBI, POLB, SAR, and OKYO
Should you be buying ImmuPharma stock or one of its competitors? The main competitors of ImmuPharma include e-therapeutics (ETX), Tissue Regenix Group (TRX), SkinBioTherapeutics (SBTX), Collagen Solutions plc (COS.L) (COS), C4X Discovery (C4XD), 4D pharma (DDDD), Ondine Biomedical (OBI), Poolbeg Pharma (POLB), Sareum (SAR), and OKYO Pharma (OKYO). These companies are all part of the "biotechnology" industry.
ImmuPharma vs.
ImmuPharma (LON:IMM) and e-therapeutics (LON:ETX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, community ranking, analyst recommendations, dividends, media sentiment, earnings, institutional ownership and valuation.
e-therapeutics' return on equity of -38.75% beat ImmuPharma's return on equity.
17.4% of ImmuPharma shares are held by institutional investors. Comparatively, 26.5% of e-therapeutics shares are held by institutional investors. 48.3% of ImmuPharma shares are held by insiders. Comparatively, 59.4% of e-therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
ImmuPharma has a beta of 1.53, indicating that its share price is 53% more volatile than the S&P 500. Comparatively, e-therapeutics has a beta of 0.46, indicating that its share price is 54% less volatile than the S&P 500.
ImmuPharma has higher earnings, but lower revenue than e-therapeutics. ImmuPharma is trading at a lower price-to-earnings ratio than e-therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, ImmuPharma had 17 more articles in the media than e-therapeutics. MarketBeat recorded 17 mentions for ImmuPharma and 0 mentions for e-therapeutics. ImmuPharma's average media sentiment score of 0.29 beat e-therapeutics' score of 0.00 indicating that ImmuPharma is being referred to more favorably in the media.
ImmuPharma received 138 more outperform votes than e-therapeutics when rated by MarketBeat users. Likewise, 76.44% of users gave ImmuPharma an outperform vote while only 60.09% of users gave e-therapeutics an outperform vote.
Summary
ImmuPharma beats e-therapeutics on 8 of the 13 factors compared between the two stocks.
Get ImmuPharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ImmuPharma Competitors List
Related Companies and Tools
This page (LON:IMM) was last updated on 1/15/2025 by MarketBeat.com Staff
Free IMM Stock Alerts